JFB 2012
Orléans, France 24-25 mai 2012
Accueil des participants
Séance inaugurale
Session Chair:
L01 - Novel 5-HT7 antagonists for the treatment of migraine
OC01 - Synthese de molecules d'intérêt pharmaceutique. Contribution à la synthèse des bastadines
Pause café et communications par affiches, session 1
Session Chair:
L02 - Foldamers: Expanding the Chemical Space
OC02 - Design, synthesis and biological evaluation of pyrazole-based kinase inhibitors
OC03 - Design, synthesis and pharmacological evaluation of EGFR/VEGFR tyrosine kinase dual inhibitors
Déjeuner
Session Chair:
OC04 - Synthesis of new molecular tools for the orphan receptor GLIC, homologous protein of the nicotinic acetylcholine receptors
OC05 - New alpha-galactosylceramides with potent immunoregulatory activity : synthesis and biological evaluation
OC06 - Study of N1-alkylation of indoles from the reaction of 2(or 3)-aminoindole-3-(or 2)carbonitriles with DMF-dialkylacetals
Pause café et communications par affiches, session 2
Session Chair:
L03 - Promoting Immune Rejection of Tumors by Blocking Tryptophan Catabolism by IDO and TDO
Remise du prix des Journées Franco-belges de pharmacochimie
Communication orale du lauréat
Clôture de la séance
Banquet
Session Chair:
L04 - Development of cyclin dependent kinase inhibitors. Investigation of their molecular mechanism of action
OC07 - Conception, synthese et evaluation de composes ciblant les ADN methyltransferases
OC08 - Activite antibacterienne, antioxyante et toxicite aiguë de quelques flavonoïdes
Pause café et communication par affiche, session 3
Session Chair:
L05 - 3D pharmacophores in computational drug design: tools for hit discovery and lead optimization
OC09 - Identification by a SOSA library screening and structure-activity relationships of succinic acid receptor (SUCNR1 or GPR91) agonist
OC10 - From the conception of FAAH inhibitors to the discovery of a novel class of selective CB2 cannabinoid receptor agonists in the treatment of experimental colitis
OC11 - Rational design of myeloperoxidase inhibitors using structure-based virtual screening
Déjeuner
Session Chair:
OC12 - In vitro characterisation of anticancer properties relating to ferrocenyl and ferrocenophane complexes
OC13 - Assessing the free brain/free plasma ratio in vitro in early drug discovery
L06 - Métabolomique et Chimie Médicinale, vers la découverte de nouvelles cibles thérapeutiques potentielles : application à la Dégénérescence Maculaire Liée à l’Age (DMLA)
Remise des prix des meilleures communications par affiche
Clôture du congrès